Amphastar Pharmaceuticals, Inc. financials

  1. Home
  2. Financials
  3. AMPH
AMPH CIK 0001297184

Source: EDGAR filings · Built 2026-06-02T02:19:39Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 121.08M 172.18M 145.18M 64.91M 70.23M 23.04M
EBITDA 197.10M 258.39M 222.72M 120.09M 80.11M 19.98M
Working Capital 477.86M 360.31M 264.19M 283.46M 214.31M 167.48M
Net Debt 495.40M 511.04M 493.12M -51.97M -20.09M -25.37M
Gross Margin 49.46% 51.08% 54.49% 49.87% 45.63% 40.97%
Operating Margin 19.50% 28.06% 30.57% 21.54% 15.96% 3.13%
Net Margin 13.63% 21.79% 21.34% 18.31% 14.19% 0.40%
Return on Equity (ROE) 12.44% 21.78% 21.51% 17.29% 13.94% 0.35%
Return on Assets (ROA) 6.02% 10.11% 9.09% 12.32% 9.25% 0.22%
Current Ratio 4.02× 3.07× 2.17× 3.99× 3.06× 2.49×
Debt-to-Equity 0.84× 0.90× 1.00× 0.20× 0.24× 0.17×
Effective Tax Rate 20.65% 15.64% 18.58% 20.23% 24.52% 76.34%
Cash Conversion Ratio 1.59× 1.34× 1.33× 0.98× 1.58× 40.82×
Accruals Ratio -0.04× -0.03× -0.03× 0.00× -0.05× -0.09×
SBC % of Revenue 3.79% 3.33% 3.14% 3.58% 4.27% 5.86%
CapEx Coverage 4.46× 5.18× 4.79× 3.67× 3.53× 1.67×
Free Cash Flow Per Share $2.51 $3.31 $2.74 $1.24 $1.41 $0.47

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 13.19× 12.13× 23.79× 16.10× 18.63× 670.33×
P/FCF 10.66× 11.23× 22.58× 22.63× 16.51× 42.87×
FCF Yield 9.38% 8.91% 4.43% 4.42% 6.06% 2.33%
EV / EBITDA 8.72× 8.82× 15.56× 10.79× 13.62× 46.53×
P/S 1.70× 2.42× 4.61× 2.70× 2.54× 2.73×
P/B 1.55× 2.41× 4.65× 2.55× 2.49× 2.37×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 719.89M 731.97M 644.39M 498.99M 437.77M 349.85M
Cost of Revenue 363.83M 358.11M 293.27M 250.13M 238.03M 206.51M
Gross Profit 356.06M 373.86M 351.12M 248.86M 199.74M 143.34M
Research and Development Expense 85.84M 73.91M 73.74M 74.77M 60.93M 67.23M
Operating Expenses 215.65M 168.44M 154.13M 141.36M 129.85M 132.39M
Operating Income (Loss) 140.40M 205.42M 196.99M 107.50M 69.89M 10.95M
Income Tax Expense (Benefit) 25.53M 29.67M 31.83M 23.48M 20.63M 3.54M
Net Income (Loss) Attributable to Parent 98.09M 159.52M 137.54M 91.39M 62.12M 1.40M
Earnings Per Share, Basic $2.10 $3.29 $2.85 $1.88 $1.30 $0.03
Weighted Average Number of Shares Outstanding, Basic 46.74M 48.43M 48.27M 48.55M 47.78M 47.04M
Earnings Per Share, Diluted $2.03 $3.06 $2.60 $1.74 $1.25 $0.03
Weighted Average Number of Shares Outstanding, Diluted 48.22M 52.06M 53.00M 52.43M 49.78M 49.12M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 170.18M 151.61M 144.30M 156.10M 126.35M 92.64M
Assets, Current 636.02M 534.07M 489.60M 378.32M 318.12M 279.68M
Assets 1.63B 1.58B 1.51B 741.99M 671.53M 631.24M
Liabilities, Current 158.16M 173.76M 225.41M 94.86M 103.81M 112.20M
Long-term Debt, Excluding Current Maturities 619.71M 613.53M 603.17M 76.64M 78.19M 45.92M
Liabilities 840.49M 845.17M 873.49M 213.33M 226.01M 182.51M
Stockholders' Equity Attributable to Parent — — — — 445.52M 402.31M
Common Stock, Shares, Outstanding 45.65M 47.62M 48.07M 48.11M 47.71M 47.50M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 156.12M 213.39M 183.50M 89.18M 97.99M 57.27M
Payments to Acquire Property, Plant, and Equipment 34.88M 41.04M 38.17M 24.03M 27.46M 33.85M
Net Cash Provided by (Used in) Investing Activities -70.33M -124.93M -649.12M -32.78M -28.67M -36.41M
Payments for Repurchase of Common Stock 75.59M 85.46M 58.14M 39.91M 28.87M 24.43M
Net Cash Provided by (Used in) Financing Activities -67.42M -80.95M 454.09M -26.44M -37.02M -2.25M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (AMPH CIK 0001297184), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

FNWD

Finward Bancorp

PDSB

PDS Biotechnology Corp

AFRM

Affirm Holdings, Inc.